AtaiBeckley Inc.·4

Jun 29, 6:00 PM ET

Craig Kevin James 4

4 · AtaiBeckley Inc. · Filed Jun 29, 2026

Research Summary

AI-generated summary of this filing

Updated

AtaiBeckley (ATAI) CMO Craig James Exercises Options, Sells Shares

What Happened
Craig Kevin James, Chief Medical Officer of AtaiBeckley Inc. (ATAI), exercised a total of 42,579 option shares and sold the same 42,579 shares on June 25, 2026. He exercised 33,051 options at $1.50 (cost $49,577) and 9,528 options at $1.18 (cost $11,243), for total exercise cash paid of $60,820. He then sold those 42,579 shares in open-market transactions at a weighted average price of $4.51, receiving about $192,031 in proceeds.

Key Details

  • Transaction date: 2026-06-25 (Form filed 2026-06-29 — appears timely; two-business-day filing window).
  • Exercises: 33,051 shares @ $1.50 (total $49,577) and 9,528 shares @ $1.18 (total $11,243).
  • Sale: 42,579 shares sold at a weighted average price $4.51; reported sale range $4.50–$4.54; total proceeds ≈ $192,031 (footnote F2).
  • Post-transaction shares beneficially owned: not disclosed in the data provided in this summary (not specified in the supplied items).
  • Footnotes: trades executed under a Rule 10b5‑1 trading plan adopted Dec 19, 2025 (F1). Vesting schedules noted for the options (F3, F4).

Context
The filing shows a same‑day exercise of options followed by sale of the acquired shares — effectively a cashless exercise (exercise + immediate disposition). M-coded entries indicate option exercises; the $0 “disposition” lines correspond to the derivative (option) being converted/exercised. The 10b5‑1 plan note means the trades were prearranged under an affirmative defense plan rather than ad hoc market timing. This appears to be a routine monetization of vested options rather than an open-market purchase signaling increased insider confidence.

Insider Transaction Report

Form 4
Period: 2026-06-25
Craig Kevin James
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-25$1.50/sh+33,051$49,57741,488 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-06-25$1.18/sh+9,528$11,24351,016 total
  • Sale

    Common Stock

    [F2]
    2026-06-25$4.51/sh42,579$192,0318,437 total
  • Exercise/Conversion

    Stock Option

    [F1][F3]
    2026-06-2533,051673,808 total
    Exercise: $1.50Exp: 2035-03-03Common Stock (33,051 underlying)
  • Exercise/Conversion

    Stock Option

    [F1][F4]
    2026-06-259,52828,608 total
    Exercise: $1.18Exp: 2033-03-14Common Stock (9,528 underlying)
Footnotes (4)
  • [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
  • [F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
  • [F3]The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
  • [F4]The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
Signature
/s/ Ryan Barrett, as attorney in fact|2026-06-29

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4